Ola Blixt, Ph.D. @ Combotope Therapeutics

Combotope Therapeutics for truly tumor-specific monoclonal antibodies

[Ola Blixt, Ph.D. @ Combotope Therapeutics @combotope]

Thanks to hard work from our DTU team, we are excited to join forces with CiMaas on CAR-NK cell therapy targeting underglycosylated Mucin-1. Our collaboration aims to advance cancer research and improve immunotherapy outcomes

[CiMaas BV @CiMaas_BV]

CiMaas receives exclusive option for the use of high affinity antibody structures in immune cells, including CAR-NK and CAR-T cells https://t.co/o3yWS0NMeb